News and Trends 30 Mar 2015
#BioFigures: €406 Million Antibody-drug conjugate Deal struck by ImmunoGen andTakeda
WHO? ImmunoGen is a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology. The Company’s uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The first product with ImmunoGen’s ADC technology is Roche‘s Kadcyla. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds […]
